BOLT
BOLT clinical trials: Bolt Biotherapeutics, Inc.
Every trial on ClinicalTrials.gov where Bolt Biotherapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BOLT on the catalyst calendar · BOLT registry changes
- Primary completion May 2027Sponsor estimatePhase 1/Phase 2NCT06921837A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal CancerBolt Biotherapeutics, Inc. · Gastric Cancer Adenocarcinoma MetastaticRecruitingBOLTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2025ActualPhase 1NCT06052852Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesBolt Biotherapeutics, Inc. · Triple Negative Breast CancerTerminatedBOLTLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 20, 2024ActualPhase 2NCT05954143Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerBolt Biotherapeutics, Inc. · Metastatic Breast CancerTerminatedBOLTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2024ActualPhase 1/Phase 2NCT04278144A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsBolt Biotherapeutics, Inc. · HER2-positive Solid TumorsTerminatedBOLTLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner